Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
We could prevent millions of cancer deaths with knowledge we already have

Cutting-edge breakthroughs are still vital in medicine, but we have many ways to prevent and cure cancer that aren’t globally accessible – but should be.

Published
18 October 2016
From
The Guardian
Punjab hepatitis control programme on verge of collapse

Punjab is facing a grave threat of Hepatitis C due to mismanagement of funds, as Rs 1,476 million have still not been utilised for the treatment of needy patients, raising serious question marks on the provincial government's health priority.

Published
18 October 2016
From
Daily Times
People infected by hepatitis C in Canada have limited access to direct-acting antivirals

A study conducted by researchers at the University of Montreal Hospital Research Centre (CRCHUM), The Kirby Institute at UNSW Australia, and the Canadian Network on Hepatitis C (CanHepC) shows that nearly everywhere in Canada, provinces and territories impose obstacles to the reimbursement of these medications by the public system because of their cost.

Published
17 October 2016
From
CRCHUM Montreal
Hepatitis B testing should be done before hepatitis C treatment due to risk of HBV reactivation

People considering direct-acting antiviral (DAA) therapy for hepatitis C should first be tested for hepatitis B virus (HBV) and monitored throughout therapy, as elimination of hepatitis C virus

Published
07 October 2016
By
Liz Highleyman
European regulator amends some Gilead hep C patent claims

In a setback for Gilead Sciences, European regulators decided not to uphold all of its patent claims for the best-selling Sovaldi hepatitis C treatment, a move that could lead to generic versions of the medicine becoming available four years sooner than had been expected.

Published
06 October 2016
From
STAT
HCV Drugs May Reactivate HBV, FDA Warns

Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

Published
06 October 2016
From
Medscape (free registration required)
100% cure rate for people with HCV genotype 1 treated with AL-335, odalasvir and simeprevir for 6 or 8 weeks

A triple regimen containing two experimental hepatitis C drugs – AL-335 and odalasvir – plus simeprevir taken for either 6 or 8 weeks cured all participants with

Published
05 October 2016
By
Liz Highleyman
UNITAID and FIND launch initiative to improve diagnostics and treatment for hepatitis C

The US $38.3 million project will support the development of better, simpler, diagnostic tools for HCV where people seek care, and will introduce HCV testing and treatment over three and a half years in HIV programmes in seven countries: Cameroon, Georgia, India, Malaysia, Myanmar, Thailand and Vietnam.

Published
04 October 2016
From
UNITAID
Elimination of viral hepatitis by 2030: What's needed and how do we get there?

This first European Action Plan provides an important driver to aid countries in their fight against viral hepatitis, to which ECDC had the opportunity to contribute directly. Currently, the available surveillance data show ongoing transmission of hepatitis in Europe and in order to interrupt this chain and to prevent further infections, European countries need to strengthen local prevention and control practices as outlined in the plan.

Published
04 October 2016
From
European Centre for Disease Prevention and Control (ECDC)
Hepatitis C infection and reinfection among men who have sex with men need higher priority, US and European studies show

Public health officials in Michigan have identified a cluster of more than 20 cases of apparently sexually transmitted hepatitis C virus (HCV) infection among HIV-positive gay and

Published
30 September 2016
By
Liz Highleyman

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.